Congo vs Syrian Arab Republic: Average cost of multi drug-resistant tuberculosis treatment
Congo
726 constant 2022 US$
in 2024
Syrian Arab Republic
785 constant 2022 US$
in 2024
Congo rank
66th
Syrian Arab Republic rank
63rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Congo
- Syrian Arab Republic
How they compare
Syrian Arab Republic currently reports 785 constant 2022 US$ against 726 constant 2022 US$ in Congo, a difference of 59 constant 2022 US$.
That makes Syrian Arab Republic's figure about 1.1 times Congo's.
The two have swapped places 1 time across 8 shared years of data; in 2017 it was Congo ahead.
Congo ranks 66th and Syrian Arab Republic ranks 63rd of 92 countries.
Syrian Arab Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Congo | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,793 constant 2022 US$ | 3,000 constant 2022 US$ | 1,207 constant 2022 US$ | Syrian Arab Republic |
| 2020s | 671.8 constant 2022 US$ | 4,182 constant 2022 US$ | 3,510 constant 2022 US$ | Syrian Arab Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Congo or Syrian Arab Republic?
- Syrian Arab Republic, at 785 constant 2022 US$ against 726 constant 2022 US$ in Congo as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Congo and Syrian Arab Republic?
- 59 constant 2022 US$, with Syrian Arab Republic ahead.
- How many years of comparable data are there for Congo and Syrian Arab Republic?
- 8 years are reported by both, from 2017 to 2024.
- How do Congo and Syrian Arab Republic rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Congo ranks 66th and Syrian Arab Republic ranks 63rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.